Arkolith/Insider Trading/OCX/Form 4

Andrews Ronald Asbury

Former CEO, DirectorOncocyte Corp (OCX) · full profile →Form 4 · filed Dec 9, 2022
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
12
1 non-derivative · 11 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Dec 1, 2022Option exercise(M)250K—$0583K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Dec 7, 2022Grant(A)50K—$050K
Dec 1, 2022Disposed to issuer(D)300K—$00
Dec 1, 2022Disposed to issuer(D)500K—$00
Dec 1, 2022Disposed to issuer(D)20K—$00
Dec 1, 2022Disposed to issuer(D)50K—$00
Dec 1, 2022Disposed to issuer(D)950K—$00
Dec 1, 2022Disposed to issuer(D)94K—$0281K
Dec 1, 2022Disposed to issuer(D)35K—$00
Dec 1, 2022Disposed to issuer(D)250K—$0250K
Dec 1, 2022Disposed to issuer(D)45K—$00
Dec 1, 2022Option exercise(M)250K—$00

Transaction Codes

M
Option exercise / conversion
A
Grant / award
D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001493152-22-035089) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML